CCR5 Antagonist: NIH. CCR5 Antagonist | NIH. (n.d.). https://clinicalinfo.hiv.gov/en/glossary/ccr5-antagonist.
CDC (n.d.) ART Adherence. Retrieved 5/17/2021 from https://www.cdc.gov/hiv/clinicians/treatment/art-adherence.html
CDC (n.d.) About PEP. Retrieved 5/17/2021 from https://www.cdc.gov/hiv/basics/pep/about-pep.html
CDC (n.d.) HIV Basics. Retrieved 5/17/2021 from https://www.cdc.gov/hiv/basics/whatishiv.html
Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018.
CLINICAL INFO.HIV.GO. (n.d.) Glossary. Drug Classes. Retrieved 5/17/2021 from https://clinicalinfo.hiv.gov/en/glossary/drug-class.
Common and/or Severe Adverse Effects Associated with Antiretroviral Therapy. NIH. (n.d.). https://clinicalinfo.hiv.gov/en/table/table-17-common-andor-severe-adverse-effects-associated-antiretroviral-therapy.
Comprehensive, up-to-date information on HIV/AIDS treatment and prevention from the University of California San Francisco. Interactions between Nutritional supplements/herbs and Antiretrovirals. (n.d.). http://hivinsite.ucsf.edu/insite?page=ar-00-02&post=10¶m=8.
Esposito, F., Corona, A., & Tramontano, E. (2012, June 20). HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. Molecular Biology International. https://www.hindawi.com/journals/mbi/2012/586401/fda. (2018). FDA approves new HIV treatment for patients who have limited treatment options. Press Announcements . https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options.
List of Nucleoside reverse transcriptase inhibitors (NRTIs). Drugs.com. (n.d.). https://www.drugs.com/drug-class/nrtis.html.
List of Protease inhibitors. Drugs.com. (n.d.). https://www.drugs.com/drug-class/protease-inhibitors.html.
HIV Fusion Inhibitors: Drug Bank. (n.d.). https://go.drugbank.com/categories/DBCAT000220
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/what-start-initial-combination-regimens-antiretroviral-naive
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Accessed (5/22/2021) https://clinicalinfo.hiv.gov/sites/default/files/inline-files/AdultandAdolescentGL.pdf
Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed (5/17/21)
U.S. Department of Health and Human Services. (2020, March 11). Newer anti-HIV drugs safest, most effective during pregnancy. National Institutes of Health. https://www.nih.gov/news-events/news-releases/newer-anti-hiv-drugs-safest-most-effective-during-pregnancy.
Virologic Failure: NIH. Virologic Failure | NIH. (n.d.). https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/virologic-failure?view=full.